BIMEKIZUMAB EFFICACY BY BODY REGION IN PLAQUE PSORIASIS: COMPARATIVE ANALYSES FROM FOUR PHASE 3/3B STUDIES

被引：0
|
作者：
Savage, Laura [1 ]
Pinter, Andreas [2 ]
Crowley, Jeffrey [3 ]
Kerkhof, Peter van de [4 ]
Armstrong, April [5 ]
Kavanagh, Sarah [6 ]
Wiegratz, Susanne [7 ]
Hoepken, Bengt [7 ]
Warren, Richard B. [8 ,9 ]
机构：
[1] Leeds Teaching Hosp NHS Trust, Leeds, England
[2] Univ Hosp Frankfurt, Frankfurt, Germany
[3] Bakersfield Dermatol, Bakersfield, CA USA
[4] Radboud Univ Nijmegen, Nijmegen, Netherlands
[5] Univ Calif Los Angeles UCLA, Los Angeles, CA USA
[6] UCB Pharm, Morrisville, NY USA
[7] UCB Pharm, Monheim, Germany
[8] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, England
[9] Manchester Univ NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester Acad Hlth Sci Ctr Manchester, Manchester, England
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
DOUBLE-BLIND; MULTICENTER; MODERATE; SAFETY;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-061
引用
收藏
页数：102
相关论文
共 50 条
  • [1] BIMEKIZUMAB SIMULTANEOUS SKIN AND NAIL CLEARANCE IN PATIENTS WITH PSORIASIS: ASSESSING COMPARATIVE EFFICACY IN FOUR PHASE 3/3B STUDIES
    Merola, Joseph F.
    Warren, Richard B.
    Thaci, Diamant
    Gordon, Kenneth B.
    Nishida, Emi
    Strober, Bruce
    Conrad, Curdin
    Kavanagh, Sarah
    Pinto, Jose Manuel Lopez
    Hoepken, Bengt
    Gisondi, Paolo
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [2] Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data
    Leonardi, Craig
    Armstrong, April
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
  • [3] Bimekizumab efficacy in difficult-to-treat areas of the body in patients with moderate to severe plaque psoriasis: change from baseline over two years pooled from five phase 3 and 3b studies
    Lauffer, Felix
    Pinter, Andreas
    Kokolakis, Georgios
    Gerdes, Sascha
    Hoepken, Bengt
    Tilt, Nicola
    Wiegratz, Susanne
    Hinze, Florian
    Sebastian, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 57 - 58
  • [4] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Merola, Joseph F.
    Elewski, Boni
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
  • [5] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
  • [6] BIMEKIZUMAB EFFICACY IN MODERATE TO SEVERE PLAQUE PSORIASIS: IMPROVEMENTS IN FATIGUE OBSERVED IN TWO PHASE 3 STUDIES
    Gottlieb, Alice B.
    Augustin, Matthias
    Lambert, Jo
    Pinter, Andreas
    Savage, Laura J.
    Tsai, Tsen-Fang
    Foley, Peter
    Paul, Carle
    Warham, Rhys
    Lambert, Jeremy
    Wiegratz, Susanne
    Stahle, Mona
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [7] Bimekizumab efficacy and safety through 2 years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
    Penas, Pablo Fernandez
    Gordon, Kenneth B.
    Armstrong, April W.
    Lebwohl, Mark
    Blauvelt, Andrew
    Paul, Carle
    Wang, Maggie
    Vanvoorden, Veerle
    Madden, Cynthia
    Gomez, Natalie Nunez
    Deherder, Delphine
    Thaci, Diamant
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 20 - 20
  • [8] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the openlabel extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
  • [9] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
    Kern, Johannes S.
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 19
  • [10] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
12345